Upstream Bio to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Upstream Bio (Nasdaq: UPB) said CEO Rand Sutherland, MD will participate in three investor events in November 2025: Truist Securities BioPharma Symposium in New York on Nov 6, 2025 at 8:10 a.m. ET (panel); Stifel 2025 Healthcare Conference in New York on Nov 11, 2025 at 9:20 a.m. ET (presentation); and TD Cowen Immunology and Inflammation Summit (virtual) on Nov 12, 2025 at 10:30 a.m. ET (fireside chat).

Live webcasts of the Stifel and Cowen presentations will be available under the Events tab in the Investors section of Upstream Bio’s website on the day of each event, and replays will be posted after the presentations.

WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November:

• 2025 Truist Securities BioPharma Symposium, New York, NY
  Thursday, November 6, 2025, Panel - 8:10 a.m. ET
• Stifel 2025 Healthcare Conference, New York, NY
  Tuesday, November 11, 2025, Presentation - 9:20 a.m. ET

• TD Cowen Immunology and Inflammation Summit, Virtual
  Wednesday, November 12, 2025, Fireside Chat - 10:30 a.m. ET
  
  

Live webcasts of the Stifel and Cowen presentations will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay of the webcasts will be posted on the Company's website following the presentations.

About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
ir@upstreambio.com

FAQ

When will Upstream Bio (UPB) present at the Stifel 2025 Healthcare Conference?

Upstream Bio will present on Nov 11, 2025 at 9:20 a.m. ET at the Stifel 2025 Healthcare Conference in New York.

How can investors watch Upstream Bio (UPB) presentations from November 2025?

Live webcasts for the Stifel and TD Cowen sessions will be available under the Events tab on Upstream Bio’s Investors website, with replays posted after each presentation.

What events will Upstream Bio CEO Rand Sutherland attend in November 2025?

Rand Sutherland will join the Truist BioPharma Symposium (Nov 6 panel), Stifel Healthcare Conference (Nov 11 presentation), and TD Cowen Immunology and Inflammation Summit (Nov 12 fireside chat).

Is the TD Cowen Immunology and Inflammation Summit Upstream Bio (UPB) session in person or virtual?

The TD Cowen session featuring Upstream Bio is virtual and scheduled for Nov 12, 2025 at 10:30 a.m. ET.

Will Upstream Bio (UPB) provide replays of its November 2025 conference presentations?

Yes. Replays of the Stifel and Cowen webcasts will be posted on the company’s website after the presentations.

What time is Upstream Bio (UPB) on the Truist Securities BioPharma Symposium agenda?

Upstream Bio’s CEO is scheduled for a panel at the Truist Securities BioPharma Symposium on Nov 6, 2025 at 8:10 a.m. ET in New York.